Q1 2024 13F Holders as of 3/31/2024
-
Type / Class
-
Equity / Class A Common Stock, par value $0.001 per share
-
Shares outstanding
-
64M
-
Number of holders
-
50
-
Total 13F shares, excl. options
-
11.9M
-
Shares change
-
-4.24M
-
Total reported value, excl. options
-
$34.3M
-
Value change
-
-$12.6M
-
Number of buys
-
20
-
Number of sells
-
-30
-
Price
-
$2.89
Significant Holders of Immuneering Corp - Class A Common Stock, par value $0.001 per share (IMRX) as of Q1 2024
57 filings reported holding IMRX - Immuneering Corp - Class A Common Stock, par value $0.001 per share as of Q1 2024.
Immuneering Corp - Class A Common Stock, par value $0.001 per share (IMRX) has 50 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 11.9M shares
of 64M outstanding shares and own 18.56% of the company stock.
Largest 10 shareholders include Cormorant Asset Management, LP (3.3M shares), CITADEL ADVISORS LLC (1.88M shares), BlackRock Inc. (1.38M shares), VANGUARD GROUP INC (1.2M shares), PRICE T ROWE ASSOCIATES INC /MD/ (910K shares), GEODE CAPITAL MANAGEMENT, LLC (463K shares), GOLDMAN SACHS GROUP INC (454K shares), STATE STREET CORP (377K shares), HighVista Strategies LLC (255K shares), and FMR LLC (233K shares).
This table shows the top 50 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.